

Bonerge launches Dihydroberberine ingredient for metabolic health supplements

12 July 2024 | News

Dihydroberberine, GlucoVest's active component, is a Berberine derivative with similar benefits



Dihydroberberine, GlucoVest's active component, is a Berberine derivative with similar benefits

Bonerge Lifescience announced the launch of its new branded ingredient, GlucoVest, designed to support blood sugar and lipid metabolism as well as weight management. As Berberine and its so-called "natural Ozempic" gain viral popularity on TikTok, many supplement brands incorporate Berberine into their products. To meet the increasing demand for higher quality products, Bonerge introduces GlucoVest, a superior Dihydroberberine ingredient, offering a new option for supplement brands.

Dihydroberberine, GlucoVest's active component, is a Berberine derivative with similar benefits. Importantly, Dihydroberberine has better bioavailability than Berberine. Unlike Berberine, which has been reported to cause side effects such as vomiting, Dihydroberberine has no report of adverse effects in published toxicology studies.

Berberine's surge in popularity is due to its weight loss mechanism similar to Semaglutide's. As both of them can boost the secretion of GLP-1, GLP-1 increases satiety, reduces food intake, enhances energy expenditure, and delays gastric emptying time. Besides its weight loss effects, research indicates that Berberine can improve insulin sensitivity, reduce blood sugar levels⁴, and enhance lipid metabolism by promoting the conversion of white fat to brown fat and lowering plasma LDL cholesterol, free fatty acids, and total cholesterol levels.